Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that its president and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:30 am ET in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that its president and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:30 am ET in New York, NY.
The presentation will be available via live webcast on Rigel's Investor Relations website.
Founded in 1996 and based in South San Francisco, Rigel focuses on developing therapies for hematologic disorders and cancer. For more information, visit www.rigel.com.
Positive
- Rigel's participation at Jefferies Global Healthcare Conference may increase visibility among investors and stakeholders.
- Opportunity to present recent developments in hematologic and cancer therapies.
Negative
- No new clinical or financial data disclosed in the PR.
- Potential investors might find the PR lacking in detailed business updates or performance metrics.
Details
News Market Reaction – RIGL
The recorded move for RIGL in the trading session of this news was +2.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 212.600.1902
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-global-healthcare-conference-302158864.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.